“…Four studies were performed in Indian populations [46,56,57,65]. Two studies each were performed in the following populations; Korean [49,55], HIV positive [33,54], high cardiac risk [34,58 ▪▪ ], fasting participant [37,38], hyperlipidaemic [43 ▪▪ ,47], Turkish [40,60], adults [30 ▪▪ ][66] and in children [10,44]. One study each was performed in the following populations; patients with coronary artery disease [31], renal disease [48], Hungarians [31], patients from the National Health and Nutrition examination survey [36], Persian cohort study patients [39], patients with acute MI [41,44], cardiology patients [36,45 ▪▪ ], those treated with PCSK-9 inhibitors [27], South African [9 ▪ ], Italian [31], Nigerian [50], Croatian [32], Slovakian [51], Lebanese [52 ▪ ], machine learning comparison, [53], a specialized lipid cohort [59], patients with hypertriglyceridaemia [61] and patients that received alirocumab, placebo, ezetimibe or a statin [2 ▪▪ ].…”